Axis Research & Technologies Appoints Dr. Mark G. Freeman as Chief Medical Advisor

Medical technology company expands strategic leadership team, medical device and surgical outreach abilities with expert clinical guidance

Axis Research & Technologies, a premier bioskills training and cadaver lab supporting medical device research and training, is proud to introduce Dr. Mark G. Freeman as the company’s Chief Medical Advisor. As a board-certified orthopedic surgeon and practicing physician with Erlanger Health System, Dr. Freeman brings a unique perspective, expert clinical guidance, and surgical expertise to the revolutionary medical education labs.

Dr. Freeman has built a strong reputation for excellence with his ability to manage complex conditions including primary and revision surgeries, fractures, and musculoskeletal infections. With a biomedical engineering degree in addition to his medical education, Dr. Freeman serves as a research abstract reviewer for the American Association of Hip and Knee Surgeons, has clinical and lab research interests, and collaborates with the biomedical device and technology industry.

Well-respected across the United States for its work in supporting research, development and medical education, Axis has tapped Dr. Freeman to provide clinical input and strategic advice for enhancing labs or events from the perspective of a practicing surgeon. Additionally, Axis  serves the didactic and cadaveric training needs of medical device companies. Dr. Freeman’s interest in supporting visiting surgeons are a natural outgrowth of his own commitment to remaining a lifelong learner and encouraging the same in others.

“Axis is very fortunate to be working with Dr. Freeman,” said Nick Moran, CEO of Axis. “His status in the community and the market, his credibility as a practicing physician and his understanding of the needs of our medical device and surgical clients give us an unparalleled view into providing a full-service experience for every company or team that enters one of our bioskills labs.”

Dr. Freeman also serves as a liaison between Axis and universities, healthcare systems, academic facilities and surgery centers that will benefit from the capabilities, technologies and global, HIPAA-compliant training platform offered at all elite Axis facilities. Axis’ labs and event spaces are flexible and welcoming, supporting a wide range of specialties and disciplines.

“As a surgeon who continues to take advantage of every opportunity to learn, I’m deeply invested in helping Axis continually evolve its facilities to meet the changing needs of clients,” said Dr. Freeman. “As Chief Medical Advisor for Axis, I am proud to assist healthcare clients by offering them insights into how they can best optimize their labs and training experiences at Axis facilities.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version